Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Our vision is to eliminate preventable blindness. By transforming the delivery of today's eye-care, we are improving patient access to intuitive and affordable diagnostics and treatments. We believe it should be easy for doctors to deliver superior outcomes to their patients. Our technology empowers patients to care for their own vision in between doctors visits. To accomplish these goals, we develop, market and commercialize transformative innovations in diagnostics, sensing, and preventative / medical / surgical treatments for eye diseases.

We were formed in August 2020 as a joint venture between Verily Life Sciences, an Alphabet company, and Santen, a leading Japanese pharmaceutical company. We are passionate and committed to building and sustaining an inclusive and equitable working environment. Every member on our team enriches our diversity by exposing us to a broad range of views that help us understand and engage with the world, identify challenges, and to discover, design and deliver solutions. The Twenty Twenty work environment empowers our team to do their absolute best work.

AI/ML

Health Care

Twenty/Twenty Therapeutics

Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.)

Todd Whitehurst

Oleg Rumyantsev

Kevin Zee

Jeremy Chan

Diksha Goyal

Christian Gutierrez

Supriyo Sinha

Shannon Gunstream Kozinn

Satoshi Fukui

Stéphane MENDRAS

Engineering

Leadership Team

Program Management

Teams at Twenty/Twenty Therapeutics

Engineering

Leadership Team

Program Management